300016 北陆药业
已收盘 10-09 15:00:00
资讯
新帖
简况
北陆药业（300016）9月24日主力资金净卖出1.41亿元
证券之星 · 09-24
北陆药业（300016）9月24日主力资金净卖出1.41亿元
北陆药业（300016）披露获得贝美前列素滴眼液《药品注册证书》公告，9月21日股价上涨4.46%
证券之星 · 09-21
北陆药业（300016）披露获得贝美前列素滴眼液《药品注册证书》公告，9月21日股价上涨4.46%
北陆药业最新公告：获得贝美前列素滴眼液药品注册证书
证券之星 · 09-20
北陆药业最新公告：获得贝美前列素滴眼液药品注册证书
北陆药业：公司将于2026年9月14日召开2026年第二次临时股东会
证券日报 · 09-13
北陆药业：公司将于2026年9月14日召开2026年第二次临时股东会
股市必读：北陆药业（300016）9月7日董秘有最新回复
证券之星 · 09-08
股市必读：北陆药业（300016）9月7日董秘有最新回复
北陆药业：目前公司持有医未医疗19.16%的股份
证券之星 · 09-07
北陆药业：目前公司持有医未医疗19.16%的股份
北陆药业：9月3日召开业绩说明会，投资者参与
证券之星 · 09-07
北陆药业：9月3日召开业绩说明会，投资者参与
公司问答丨北陆药业：目前持有医未医疗19.16%的股份 系其第二大股东
格隆汇 · 09-03
公司问答丨北陆药业：目前持有医未医疗19.16%的股份 系其第二大股东
北陆药业：8月28日高管宗利减持股份合计1600股
证券之星 · 08-31
北陆药业：8月28日高管宗利减持股份合计1600股
北陆药业：8月27日高管宗利减持股份合计4000股
证券之星 · 08-28
北陆药业：8月27日高管宗利减持股份合计4000股
北陆药业：8月25日高管宗利减持股份合计1.1万股
证券之星 · 08-26
北陆药业：8月25日高管宗利减持股份合计1.1万股
北陆药业（300016）2026年中报简析：营收净利润同比双双增长
证券之星 · 08-26
北陆药业（300016）2026年中报简析：营收净利润同比双双增长
股市必读：北陆药业新发布《2026年半年度报告》
证券之星 · 08-26
股市必读：北陆药业新发布《2026年半年度报告》
北陆药业（300016）披露2026年半年度利润分配预案议案，8月24日股价下跌6.7%
证券之星 · 08-24
北陆药业（300016）披露2026年半年度利润分配预案议案，8月24日股价下跌6.7%
图解北陆药业中报：第二季度单季净利润同比增长125.40%
证券之星 · 08-24
图解北陆药业中报：第二季度单季净利润同比增长125.40%
北陆药业(300016)6月30日股东户数3.9万户，较上期减少4.61%
证券之星 · 08-24
北陆药业(300016)6月30日股东户数3.9万户，较上期减少4.61%
北陆药业：8月7日高管宗利减持股份合计2000股
证券之星 · 08-10
北陆药业：8月7日高管宗利减持股份合计2000股
北陆药业（300016）披露吡格列酮二甲双胍口服常释剂型拟中选第十二批全国药品集中采购公告，8月3日股价上涨0.51%
证券之星 · 08-03
北陆药业（300016）披露吡格列酮二甲双胍口服常释剂型拟中选第十二批全国药品集中采购公告，8月3日股价上涨0.51%
股市必读：北陆药业（300016）7月29日披露最新机构调研信息
证券之星 · 07-30
股市必读：北陆药业（300016）7月29日披露最新机构调研信息
北陆药业：上海证券、远东宏信等多家机构于7月28日调研我司
证券之星 · 07-29
北陆药业：上海证券、远东宏信等多家机构于7月28日调研我司
公司概况
公司名称：
北京北陆药业股份有限公司
所属行业：
医药制造业
上市日期：
2009-10-30
主营业务：
北京北陆药业股份有限公司的主营业务是对比剂系列、降糖类及原料药等化学药品以及中成药的生产、研发、营销。公司的主要产品是制剂、原料药、中枢神经类、清热解毒类、感冒类、补肾强身类、脾胃肠消化类、活血止痛类、肝胆类。
发行价格：
17.86
{"stockData":{"symbol":"300016","market":"SZ","secType":"STK","nameCN":"北陆药业","latestPrice":9.16,"timestamp":1791529407000,"preClose":9.18,"halted":0,"volume":26454800,"delay":0,"changeRate":-0.0022,"floatShares":562000000,"shares":582000000,"eps":0.2451,"marketStatus":"已收盘","change":-0.02,"latestTime":"10-09 15:00:00","open":9.13,"high":9.22,"low":8.77,"amount":238000000,"amplitude":0.049,"askPrice":9.17,"askSize":75,"bidPrice":9.16,"bidSize":1062,"shortable":0,"etf":0,"ttmEps":0.2451,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791768600000},"marketStatusCode":5,"adr":0,"adjPreClose":9.18,"symbolType":"stock","openAndCloseTimeList":[[1791509400000,1791516600000],[1791522000000,1791529200000]],"highLimit":10.1,"lowLimit":8.26,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":581689731,"isCdr":false,"pbRate":2.14,"roa":"--","peRate":37.372501,"roe":"3.4%","epsLYR":0.18,"committee":-0.244383,"marketValue":5328000000,"turnoverRate":0.0471,"status":1,"floatMarketCap":5150000000},"requestUrl":"/m/hq/s/300016/wiki","defaultTab":"wiki","newsList":[{"id":"2669450585","title":"北陆药业（300016）9月24日主力资金净卖出1.41亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2669450585","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669450585?lang=zh_cn&edition=full","pubTime":"2026-09-24 15:36","pubTimestamp":1790235406,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月24日收盘，北陆药业报收于9.84元，下跌4.37%，换手率12.66%，成交量71.17万手，成交额7.14亿元。北陆药业主营业务：对比剂制剂及原料药、中枢神经类和降糖类药品的研发、生产与销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400022016.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0042","BK0060","BK0239","300016"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669154976","title":"北陆药业（300016）披露获得贝美前列素滴眼液《药品注册证书》公告，9月21日股价上涨4.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669154976","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669154976?lang=zh_cn&edition=full","pubTime":"2026-09-21 17:36","pubTimestamp":1789983365,"startTime":"0","endTime":"0","summary":"截至2026年9月21日收盘，北陆药业报收于8.67元，较前一交易日上涨4.46%，最新总市值为50.43亿元。该股当日开盘8.35元，最高8.77元，最低8.31元，成交额达2.85亿元，换手率为5.91%。北陆药业近日披露公告，公司收到国家药品监督管理局核准签发的贝美前列素滴眼液《药品注册证书》，药品通用名称为贝美前列素滴眼液，剂型为眼用制剂，规格0.03%，注册分类为化学药品4类，视同通过仿制药质量和疗效一致性评价。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100022337.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300016","BK0046","BK0060","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668183091","title":"北陆药业最新公告：获得贝美前列素滴眼液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2668183091","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668183091?lang=zh_cn&edition=full","pubTime":"2026-09-20 16:20","pubTimestamp":1789892459,"startTime":"0","endTime":"0","summary":"北陆药业(300016.SZ)公告称，公司收到国家药品监督管理局核准签发的贝美前列素滴眼液《药品注册证书》。该药品用于降低开角型青光眼及高眼压症患者的眼压，已纳入国家医保乙类目录，2024年、2025年国内销售额分别为1862万元、1669万元。此次获批视同通过仿制药质量和疗效一致性评价，将进一步丰富公司制剂产品管线，实现眼科领域产品布局。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092000004139.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0046","BK0042","300016","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667724682","title":"北陆药业：公司将于2026年9月14日召开2026年第二次临时股东会","url":"https://stock-news.laohu8.com/highlight/detail?id=2667724682","media":"证券日报 ","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667724682?lang=zh_cn&edition=full","pubTime":"2026-09-13 20:51","pubTimestamp":1789303860,"startTime":"0","endTime":"0","summary":"证券日报网讯9月13日，北陆药业发布公告称，公司将于2026年9月14日召开2026年第二次临时股东会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-13/doc-inirszcr0132270.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-13/doc-inirszcr0132270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BK0042","300016","BK0060","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665105883","title":"股市必读：北陆药业（300016）9月7日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2665105883","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665105883?lang=zh_cn&edition=full","pubTime":"2026-09-08 01:02","pubTimestamp":1788800542,"startTime":"0","endTime":"0","summary":"截至2026年9月7日收盘，北陆药业报收于8.49元，上涨0.24%，换手率2.87%，成交量16.12万手，成交额1.37亿元。董秘最新回复投资者： 您好！不久前，《陆玉龙卓越企业研究》公众号发文《北陆药业 参股拟上市公司发展动态（二十）》披露，北陆药业对深圳医未医疗的持股比例已增加到18.73%。当日关注点交易信息汇总：9月7日北陆药业主力资金净流入39.56万元，游资资金净流入924.22万元，散户资金净流出963.78万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090800000559.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0046","BK0042","300016","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665131543","title":"北陆药业：目前公司持有医未医疗19.16%的股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2665131543","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665131543?lang=zh_cn&edition=full","pubTime":"2026-09-07 16:21","pubTimestamp":1788769271,"startTime":"0","endTime":"0","summary":"证券之星消息，北陆药业(300016)09月07日在投资者关系平台上答复投资者关心的问题。投资者提问：您好！不久前，《陆玉龙卓越企业研究》公众号发文《北陆药业 参股拟上市公司发展动态（二十）》披露，北陆药业对深圳医未医疗的持股比例已增加到18.73%。”请问，这一信息准确吗？谢谢答复！北陆药业回复：感谢您的关注。目前公司持有医未医疗19.16%的股份，系其第二大股东。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700019904.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300016","BK0060","159891","BK0042","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665391994","title":"北陆药业：9月3日召开业绩说明会，投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2665391994","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665391994?lang=zh_cn&edition=full","pubTime":"2026-09-07 13:45","pubTimestamp":1788759924,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年9月3日北陆药业发布公告称公司于2026年9月3日召开业绩说明会。北陆药业2026年中报显示，上半年度公司主营收入6.73亿元，同比上升15.26%；归母净利润7975.21万元，同比上升166.13%；扣非净利润7343.14万元，同比上升146.93%；其中2026年第二季度，公司单季度主营收入3.53亿元，同比上升17.06%；单季度归母净利润3477.63万元，同比上升125.4%；单季度扣非净利润3371.37万元，同比上升102.49%；负债率26.22%，投资收益951.93万元，财务费用1066.41万元，毛利率43.85%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700013263.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300016","BK0239","BK0042","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664878570","title":"公司问答丨北陆药业：目前持有医未医疗19.16%的股份 系其第二大股东","url":"https://stock-news.laohu8.com/highlight/detail?id=2664878570","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664878570?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:18","pubTimestamp":1788427123,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0060","BK0046","300016","BK0042","159891","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663005193","title":"北陆药业：8月28日高管宗利减持股份合计1600股","url":"https://stock-news.laohu8.com/highlight/detail?id=2663005193","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663005193?lang=zh_cn&edition=full","pubTime":"2026-08-31 21:01","pubTimestamp":1788181292,"startTime":"0","endTime":"0","summary":"证券之星消息，根据8月31日市场公开信息、上市公司公告及交易所披露数据整理，北陆药业（300016）最新董监高及相关人员股份变动情况：2026年8月28日公司高管宗利共减持公司股份1600.0股，占公司总股本为0.0003%。变动期间公司股价下跌3.53%，8月28日当日收盘报9.02元。北陆药业近半年内的董监高及核心技术人员增减持详情如下：北陆药业的高管列表及最新持股情况如下：该股最近90天内无机构评级。本文数据来源于深圳证券交易所信息披露、北陆药业公告，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100034715.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300016","BK0042","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662093020","title":"北陆药业：8月27日高管宗利减持股份合计4000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2662093020","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662093020?lang=zh_cn&edition=full","pubTime":"2026-08-28 21:01","pubTimestamp":1787922082,"startTime":"0","endTime":"0","summary":"证券之星消息，根据8月28日市场公开信息、上市公司公告及交易所披露数据整理，北陆药业（300016）最新董监高及相关人员股份变动情况：2026年8月27日公司高管宗利共减持公司股份4000.0股，占公司总股本为0.0007%。变动期间公司股价下跌1.27%，8月27日当日收盘报9.35元。北陆药业近半年内的董监高及核心技术人员增减持详情如下：北陆药业的高管列表及最新持股情况如下：该股最近90天内无机构评级。本文数据来源于深圳证券交易所信息披露、北陆药业公告，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800051200.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0060","BK0042","300016","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662714149","title":"北陆药业：8月25日高管宗利减持股份合计1.1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2662714149","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662714149?lang=zh_cn&edition=full","pubTime":"2026-08-26 21:01","pubTimestamp":1787749269,"startTime":"0","endTime":"0","summary":"证券之星消息，根据8月26日市场公开信息、上市公司公告及交易所披露数据整理，北陆药业（300016）最新董监高及相关人员股份变动情况：2026年8月25日公司高管宗利共减持公司股份1.1万股，占公司总股本为0.0019%。变动期间公司股价下跌0.31%，8月25日当日收盘报9.71元。北陆药业近半年内的董监高及核心技术人员增减持详情如下：北陆药业的高管列表及最新持股情况如下：该股最近90天内无机构评级。本文数据来源于深圳证券交易所信息披露、北陆药业公告，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600048963.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0042","300016","BK0060","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662750155","title":"北陆药业（300016）2026年中报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2662750155","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662750155?lang=zh_cn&edition=full","pubTime":"2026-08-26 06:27","pubTimestamp":1787696861,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期北陆药业发布2026年中报。根据财报显示，北陆药业营收净利润同比双双增长。截至本报告期末，公司营业总收入6.73亿元，同比上升15.26%，归母净利润7975.21万元，同比上升166.13%。按单季度数据看，第二季度营业总收入3.53亿元，同比上升17.06%，第二季度归母净利润3477.63万元，同比上升125.4%。财报体检工具显示：建议关注公司应收账款状况本文数据来源于北陆药业2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600010140.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300016"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662759561","title":"股市必读：北陆药业新发布《2026年半年度报告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662759561","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662759561?lang=zh_cn&edition=full","pubTime":"2026-08-26 01:12","pubTimestamp":1787677933,"startTime":"0","endTime":"0","summary":"2026年半年度报告披露提示性公告《2026年半年度报告》及其摘要已于2026年8月25日在中国证监会指定的创业板信息披露网站披露，《2026年半年度报告摘要》同时刊登在《中国证券报》《证券时报》及《上海证券报》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600003291.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0239","BK0060","300016","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661127497","title":"北陆药业（300016）披露2026年半年度利润分配预案议案，8月24日股价下跌6.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661127497","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661127497?lang=zh_cn&edition=full","pubTime":"2026-08-24 22:02","pubTimestamp":1787580136,"startTime":"0","endTime":"0","summary":"截至2026年8月24日收盘，北陆药业报收于9.74元，较前一交易日下跌6.7%，最新总市值为56.66亿元。该股当日开盘10.3元，最高10.72元，最低9.54元，成交额达11.35亿元，换手率为20.18%。近日，北陆药业发布《关于召开2026年第二次临时股东会的通知》。会议审议《关于2026年半年度利润分配预案的议案》，采用现场投票与网络投票相结合方式，股东可委托代理人出席。中小投资者表决将单独计票并披露。登记时间为2026年9月8日至13日，地点为公司证券部。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400036642.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300016","BK0239","BK0046","BK0042","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661203812","title":"图解北陆药业中报：第二季度单季净利润同比增长125.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661203812","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661203812?lang=zh_cn&edition=full","pubTime":"2026-08-24 17:59","pubTimestamp":1787565580,"startTime":"0","endTime":"0","summary":"证券之星消息，北陆药业2026年中报显示，上半年度公司主营收入6.73亿元，同比上升15.26%；归母净利润7975.21万元，同比上升166.13%；扣非净利润7343.14万元，同比上升146.93%；其中2026年第二季度，公司单季度主营收入3.53亿元，同比上升17.06%；单季度归母净利润3477.63万元，同比上升125.4%；单季度扣非净利润3371.37万元，同比上升102.49%；负债率26.22%，投资收益951.93万元，财务费用1066.41万元，毛利率43.85%。财报数据概要请见下图:本文数据来源于北陆药业2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400025242.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300016"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661222221","title":"北陆药业(300016)6月30日股东户数3.9万户，较上期减少4.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661222221","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661222221?lang=zh_cn&edition=full","pubTime":"2026-08-24 17:33","pubTimestamp":1787563987,"startTime":"0","endTime":"0","summary":"证券之星消息，近日北陆药业披露，截至2026年6月30日公司股东户数为3.9万户，较3月31日减少1884.0户，减幅为4.61%。在化学制药行业个股中，北陆药业股东户数高于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.66万户。从股价来看，2026年3月31日至2026年6月30日，北陆药业区间跌幅为23.3%，在此期间股东户数减少1884.0户，减幅为4.61%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400024540.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0042","BK0239","300016","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658931807","title":"北陆药业：8月7日高管宗利减持股份合计2000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2658931807","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658931807?lang=zh_cn&edition=full","pubTime":"2026-08-10 21:01","pubTimestamp":1786366886,"startTime":"0","endTime":"0","summary":"证券之星消息，根据8月10日市场公开信息、上市公司公告及交易所披露数据整理，北陆药业（300016）最新董监高及相关人员股份变动情况：2026年8月7日公司高管宗利共减持公司股份2000.0股，占公司总股本为0.0003%。变动期间公司股价上涨5.65%，8月7日当日收盘报8.41元。北陆药业近半年内的董监高及核心技术人员增减持详情如下：北陆药业的高管列表及最新持股情况如下：该股最近90天内无机构评级。本文数据来源于深圳证券交易所信息披露、北陆药业公告，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000031728.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300016","BK0239","BK0046","BK0042","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656377462","title":"北陆药业（300016）披露吡格列酮二甲双胍口服常释剂型拟中选第十二批全国药品集中采购公告，8月3日股价上涨0.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656377462","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656377462?lang=zh_cn&edition=full","pubTime":"2026-08-03 22:32","pubTimestamp":1785767537,"startTime":"0","endTime":"0","summary":"截至2026年8月3日收盘，北陆药业报收于7.85元，较前一交易日上涨0.51%，最新总市值为45.66亿元。该股当日开盘7.81元，最高7.86元，最低7.76元，成交额达7853.04万元，换手率为1.79%。公告显示，公司参加第十二批全国药品集中采购，其吡格列酮二甲双胍口服常释剂型拟中选。该产品已于2025年12月获得药品注册证书，采购周期至2029年12月31日。后续合同签订及市场销售存在不确定性，公司将及时披露进展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300037506.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300016","BK0060","BK0042","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655027890","title":"股市必读：北陆药业（300016）7月29日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2655027890","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655027890?lang=zh_cn&edition=full","pubTime":"2026-07-30 02:02","pubTimestamp":1785348140,"startTime":"0","endTime":"0","summary":"截至2026年7月29日收盘，北陆药业报收于7.82元，下跌0.38%，换手率3.29%，成交量18.47万手，成交额1.44亿元。机构调研要点：2026年一季度归母净利润同比上涨209.36%，主要因各产品线稳定增长及可转债摘牌致财务费用大幅减少。机构调研要点：亳州生产基地中药提取及中成药车间进入试生产与工艺验证阶段，预计2027年通过GMP检查并投产。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000001061.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300016","BK0046","BK0060","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655863298","title":"北陆药业：上海证券、远东宏信等多家机构于7月28日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2655863298","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655863298?lang=zh_cn&edition=full","pubTime":"2026-07-29 17:31","pubTimestamp":1785317462,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年7月29日北陆药业发布公告称上海证券刘薇、远东宏信安阳、浙商证券崔宁、广州灏达投资香莲于2026年7月28日调研我司。北陆药业2026年一季报显示，一季度公司主营收入3.2亿元，同比上升13.33%；归母净利润4497.58万元，同比上升209.36%；扣非净利润3971.77万元，同比上升203.47%；负债率28.35%，投资收益549.69万元，财务费用537.45万元，毛利率46.52%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072900029037.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["IE00BQJZWZ67.USD","LU1807302812.USD","IE00B19Z5X02.USD","LU0072913022.USD","IE00BWDBJ730.SGD","BK1186","BK0060","BK0239","LU1960683339.HKD","LU0067412154.USD","HK0000288784.HKD","LU0880133367.SGD","BK0046","LU1993786604.SGD","LU0501845795.SGD","LU1008478684.HKD","LU1152091168.USD","HK0000288743.USD","03360","LU1152091754.HKD","BK0042","300016","161027"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791723760482,"stockEarnings":[{"period":"1week","weight":-0.0418},{"period":"1month","weight":0.0718},{"period":"3month","weight":0.1254},{"period":"6month","weight":-0.0945},{"period":"1year","weight":0.0718},{"period":"ytd","weight":0.161}],"compareEarnings":[{"period":"1week","weight":-0.0074},{"period":"1month","weight":-0.0349},{"period":"3month","weight":-0.0456},{"period":"6month","weight":-0.0433},{"period":"1year","weight":-0.0305},{"period":"ytd","weight":-0.0391}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京北陆药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"38954人(较上一季度减少4.61%)","perCapita":"14432股","listingDate":"2009-10-30","address":"北京市密云区水源西路3号","registeredCapital":"58168万元","survey":" 北京北陆药业股份有限公司的主营业务是对比剂系列、降糖类及原料药等化学药品以及中成药的生产、研发、营销。公司的主要产品是制剂、原料药、中枢神经类、清热解毒类、感冒类、补肾强身类、脾胃肠消化类、活血止痛类、肝胆类。","listedPrice":17.86},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"北陆药业(300016)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供北陆药业(300016)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"北陆药业,300016,北陆药业股票,北陆药业股票老虎,北陆药业股票老虎国际,北陆药业行情,北陆药业股票行情,北陆药业股价,北陆药业股市,北陆药业股票价格,北陆药业股票交易,北陆药业股票购买,北陆药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"北陆药业(300016)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供北陆药业(300016)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}